Annovis Bio director buys 76,344 company shares

Annovis Bio director Michael B. Hoffman reported new open-market purchases of company stock.

Rhea-AI Filing Summary

Annovis Bio director Michael B. Hoffman reported new open-market purchases of company stock. On May 20, 2026, he bought a total of 76,344 shares of Annovis Bio common stock in three open-market transactions at prices between $1.75 and $1.8999 per share.

Following these transactions, Hoffman directly holds 3,364,883 shares of common stock. A separate entry also reports 223,357 shares held indirectly through The 2024 Hoffman Family Trust, over which he has voting and investment power according to the filing footnote.

Insider Trade Summary

Net Buyer: 76,344 shares

Net Buy 4 txns

Insider Hoffman Michael B

Role Director

Bought 76,344 shs ($143K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,562	$1.75	$4K
Purchase	Common Stock	18,849	$1.80	$34K
Purchase	Common Stock	54,933	$1.8999	$104K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,364,883 shares (Direct); Common Stock — 223,357 shares (Indirect, The 2024 Hoffman Family Trust)

Footnotes (1)

1. F1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

Key Figures

Total shares purchased: 76,344 shares Largest single purchase: 54,933 shares at $1.8999 Additional purchase: 18,849 shares at $1.80 +3 more

6 metrics

Total shares purchased 76,344 shares Open-market buys on May 20, 2026

Largest single purchase 54,933 shares at $1.8999 Common stock, open-market transaction

Additional purchase 18,849 shares at $1.80 Common stock, open-market transaction

Smaller purchase 2,562 shares at $1.75 Common stock, open-market transaction

Direct holdings after trades 3,364,883 shares Common stock held directly after May 20, 2026

Indirect trust holdings 223,357 shares Held via The 2024 Hoffman Family Trust

Key Terms

open-market purchase, Common Stock, indirect, voting and investment power, +1 more

5 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect financial

""ownership_type": "indirect""

voting and investment power financial

"the reporting person has voting and investment power over such shares"

family trust financial

"The shares are held in a family trust formed by the reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Annovis Bio (ANVS) disclose for Michael B. Hoffman?

Annovis Bio reported that director Michael B. Hoffman bought additional common shares. On May 20, 2026, he completed three open-market purchases totaling 76,344 shares, expanding his direct holdings while also reporting indirect holdings through The 2024 Hoffman Family Trust.

How many Annovis Bio (ANVS) shares did Michael B. Hoffman buy and at what prices?

Michael B. Hoffman bought 76,344 Annovis Bio common shares. The filing lists three open-market purchases: 54,933 shares at $1.8999, 18,849 shares at $1.80, and 2,562 shares at $1.75 per share, all executed on May 20, 2026.

What are Michael B. Hoffman’s direct Annovis Bio (ANVS) holdings after the reported purchases?

After the reported May 20, 2026 transactions, Michael B. Hoffman directly holds 3,364,883 shares of Annovis Bio common stock. This figure comes from the post-transaction share balance disclosed alongside his largest open-market purchase entry in the Form 4 filing.

Does Michael B. Hoffman have indirect Annovis Bio (ANVS) holdings through a trust?

Yes. The Form 4 shows 223,357 Annovis Bio shares held indirectly through The 2024 Hoffman Family Trust. A footnote explains that Hoffman formed the trust and retains both voting and investment power over those indirectly held shares.

What transaction code is used for Michael B. Hoffman’s Annovis Bio (ANVS) share purchases?

The filing classifies Michael B. Hoffman’s Annovis Bio transactions with code “P,” indicating open-market or private purchase. Each non-derivative transaction entry describes the activity as an open-market purchase of common stock on May 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 08:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		P		2,562	A	$1.75	3,291,101	D
Common Stock								223,357	I	The 2024 Hoffman Family Trust(1)
Common Stock	05/20/2026		P		18,849	A	$1.8	3,309,950	D
Common Stock	05/20/2026		P		54,933	A	$1.8999	3,364,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

	/s/ Maria Maccecchini Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)